Credit NIAID-RML
Highlighted Sections
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Hospitalized Adults: Therapeutic Management
The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.
Abatacept
A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Antithrombotic Therapy
The Panel revised this section based on results from the recently published ANTICOVID trial.
Infliximab
A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Hospitalized Adults: Therapeutic Management
The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.
Abatacept
A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Antithrombotic Therapy
The Panel revised this section based on results from the recently published ANTICOVID trial.
Infliximab
A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Hospitalized Adults: Therapeutic Management
The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.
Abatacept
A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Antithrombotic Therapy
The Panel revised this section based on results from the recently published ANTICOVID trial.
Infliximab
A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.